Objective To study the clinical efficacy of Heixiaoyao San in breast cancer patients with menopausal-like symptoms induced by tamoxifen treatment. Method 60 cases of breast cancer patients with menopausal-like symptoms were included in this study and were randomized into control group and observation group, with 30 cases in each. The patients of control group were given oral vitamin B1, B6 and oryzanol, while observation group was ad-ministered with Chinese medicine of Heixiaoyao San combined with Shensiwei, the estrogen levels (estradiol, follicle stimulating hormone, pituitary prolactin, luteinizing hormone) and serum tumor markers (CA15-3, CA125), as well as quality of life were measured before treatment, and after 2-month and 4-month treatment. Result The levels of all estrogen levels at each time point of both groups were similar (P> 0.05). As for the quality of life, the overall health status score (80.15±8.96 vs 45.69±11.24), function score (55.25±11.78 vs 36.85±10.29), symptoms and financial bur-den score (55.25 ± 11.78 vs 36.85 ± 10.29) were all higher in the observation group compared with the control group, and the differences were statistically significant (P < 0.05). Conclusion Heixiaoyao San combined with Shensiwei effectively improves the quality of life for breast cancer patients with menopausal-like symptoms, but has no influ-ence on levels of estrogen and tumor markers.%目的：探讨黑逍遥散联合肾四味对他莫昔芬治疗乳腺癌所致类更年期症状患者的影响。方法使用随机数字表法将60例乳腺癌伴类更年期症状的患者分为对照组和观察组，每组各30例。对照组患者接受内分泌治疗及口服维生素B1、B6、谷维素，观察组患者接受内分泌治疗及黑逍遥散及肾四味加减。持续治疗4个月后对比两组患者治疗前、治疗2个月和治疗4个月时的性激素水平（雌二醇、卵泡刺激素、垂体泌乳素、黄体生成素）、血清肿瘤标志物（CA15-3和CA125）水平及治疗前后的生活质量。结果两组患者各观察时点的性激素水平及血清肿瘤标志物水平差异均无统计学意义（P＞0.05）。治疗后，观察组与对照组的总体健康状况评分（80.15±8.96 vs 45.69±11.24）、功能评分（55.25±11.78 vs 36.85±10.29）、症状及经济状态评分（40.14±17.58 vs 65.87±12.96）相比，观察组均优于对照组，差异具有统计学意义（P＜0.05）。结论黑逍遥散联合肾四味可有效改善经他莫昔芬治疗后伴有类更年期乳腺癌患者的生活质量，对其性激素及肿瘤标志物水平并无影响。
展开▼
